Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

Overview of attention for article published in PLOS ONE, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog

patent: 2 patents

Citations

dimensions_citation: 173 Dimensions

Readers on

mendeley: 145 Mendeley

Summary News Blogs Patents Dimensions citations

So far, Altmetric has seen 1 blog post.

Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

Everyone's Blog Posts - Onco'Zine, 09 Feb 2012

Scientists at Roswell Park Cancer Institute have demonstrated that entinostat (Syndax Pharmaceuticals, Inc.), a class I…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.